LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Airley, R; Evans, AR; Mobasheri, A; Hewitt, SM
Publisher: ELSEVIER GMBH, URBAN & FISCHER VERLAG
Languages: English
Types: Article
Subjects: RC0254
The hypoxic tumor microenvironment is associated with malignant progression and poor treatment response. The glucose transporter Glut-1 is a prognostic factor and putative hypoxia marker. So far, studies of Glut-1 in cancer have utilised conventional immunohistochemical analysis in a series of individual biopsy or surgical specimens. Tissue microarrays, however, provide a rapid, inexpensive means of profiling biomarker expression. To evaluate hypoxia markers, tissue cores must show architectural features of hypoxia, i.e. viable tissue surrounding necrotic regions. Glut-1 may be a useful biomarker to validate tissue microarrays for use in studies of hypoxia-regulated genes in cancer. In this study, we carried out immunohistochemical detection of Glut-1 protein in many tumor and normal tissue types in a range of tissue microarrays. Glut-1 was frequently found in peri-necrotic regions, occurring in 9/34 lymphomas, 6/12 melanomas, and 5/16 glioblastomas; and in 43/54 lung, 22/84 colon, and 23/60 ovarian tumors. Expression was rare in breast (6/40) and prostate (1/57) tumors, and in normal tissue, was restricted to spleen, tongue and CNS endothelium. In conclusion, tissue microarrays enable the observation of Glut-1 expression in peri-necrotic regions, which may be linked to hypoxia, and reflect previous studies showing differential Glut-1 expression across tumor types and non malignant tissue.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • Ahmed, N., Berridge, M.V., 1997. Regulation of glucose transport by interleukin-3 in growth factordependent and oncogene-transformed bone marrow-derived cell lines. Leuk Res. 21, 609-618.
    • Airley, R., Loncaster, J., Davidson, S., Bromley, M., Roberts, S., Patterson, A., Hunter, R., Stratford, I., West, C., 2001. Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clin Cancer Res. 7, 928-934.
    • Airley, R.E., Loncaster, J., Raleigh, J.A., Harris, A.L., Davidson, S.E., Hunter, R.D., West, C.M., Stratford, I.J., 2003. GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: relationship to pimonidazole binding. Int J Cancer. 104, 85-91.
    • Airley, R.E., Phillips, R.M., Evans, A.E., Double, J., Burger, A.M., Feibig, H.H., West, C.M., Stratford, I.J., 2005. Hypoxia-regulated glucose transporter Glut-1 may influence chemosensitivity to some alkylating agents: results of EORTC (First Translational Award) study of the relevance of tumour hypoxia to the outcome of chemotherapy in human tumour-derived xenografts. Int J Oncol. 26, 1477-1484.
    • Albertella, M.R., Loadman, P.M., Jones, P.H., Phillips, R.M., Rampling, R., Burnet, N., Alcock, C., Anthoney, A., Vjaters, E., Dunk, C.R., Harris, P.A., Wong, A., Lalani, A.S., Twelves, C.J., 2008. Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: results of a phase I study. Clin Cancer Res. 14, 1096-1104.
    • Amann, T., Maegdefrau, U., Hartmann, A., Agaimy, A., Marienhagen, J., Weiss, T.S., Stoeltzing, O., Warnecke, C., Scholmerich, J., Oefner, P.J., Kreutz, M., Bosserhoff, A.K., Hellerbrand, C., 2009. GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis. Am J Pathol. 174, 1544-1552.
    • Baron-Delage, S., Mahraoui, L., Cadoret, A., Veissiere, D., Taillemite, J.L., Chastre, E., Gespach, C., Zweibaum, A., Capeau, J., Brot-Laroche, E., Cherqui, G., 1996. Deregulation of hexose transporter expression in Caco-2 cells by ras and polyoma middle T oncogenes. Am J Physiol. 270, G314-323.
    • Behrooz, A., Ismail-Beigi, F., 1997. J Biol Chem. 272, 5555-5562.
    • Binder, C., Binder, L., Marx, D., Schauer, A., Hiddemann, W., 1997. Deregulated simultaneous expression of multiple glucose transporter isoforms in malignant cells and tissues. Anticancer Res. 17, 4299- 4304.
    • Brizel, D.M., Scully, S.P., Harrelson, J.M., Layfield, L.J., Bean, J.M., Prosnitz, L.R., Dewhirst, M.W., 1996. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res. 56, 941-943.
    • Brown, R.S., Wahl, R.L., 1993. Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer. 72, 2979-2985.
    • Cantuaria, G., Magalhaes, A., Penalver, M., Angioli, R., Braunschweiger, P., Gomez-Marin, O., Kanhoush, R., Gomez-Fernandez, C., Nadji, M., 2000. Expression of GLUT-1 glucose transporter in borderline and malignant epithelial tumors of the ovary. Gynecol Oncol. 79, 33-37.
    • Chen, C., Pore, N., Behrooz, A., Ismail-Beigi, F., Maity, A., 2001. Regulation of glut1 mRNA by hypoxiainducible factor-1. Interaction between H-ras and hypoxia. J Biol Chem. 276, 9519-9525.
    • Chung, F.Y., Huang, M.Y., Yeh, C.S., Chang, H.J., Cheng, T.L., Yen, L.C., Wang, J.Y., Lin, S.R., 2009. GLUT1 gene is a potential hypoxic marker in colorectal cancer patients. BMC Cancer. 9, 241.
    • Cooper, R., Sarioglu, S., Sokmen, S., Fuzun, M., Kupelioglu, A., Valentine, H., Gorken, I.B., Airley, R., West, C., 2003. Glucose transporter-1 (GLUT-1): a potential marker of prognosis in rectal carcinoma? Br J Cancer. 89, 870-876.
    • Denekamp, J., Dasu, A., 1999. Inducible repair and the two forms of tumour hypoxia--time for a paradigm shift. Acta Oncol. 38, 903-918.
    • Fogt, F., Wellmann, A., Urbanski, S.J., Noffsinger, A., Poremba, C., Zimmerman, R.L., Alsaigh, N., 2001. Glut-1 expression in dysplastic and regenerative lesions of the colon. Int J Mol Med. 7, 615-619.
    • Furudoi, A., Tanaka, S., Haruma, K., Yoshihara, M., Sumii, K., Kajiyama, G., Shimamoto, F., 2001. Clinical significance of human erythrocyte glucose transporter 1 expression at the deepest invasive site of advanced colorectal carcinoma. Oncology. 60, 162-169.
  • No related research data.
  • No similar publications.

Share - Bookmark

Cite this article